HCP

BIFIDOBACTERIUM ANIMALIS SSP. LACTIS

B420™

Grant JR, Stothard P. The CGView Server: a comparative genomics tool for circular genomes. Nucleic Acids Res. 2008;36:W181-W184.

B420™ Introduction

B lactis B420™ has been documented in more than 60 scientific studies, including 16 clinical trials. It has been demonstrated in clinical trials to survive intestinal passage, and in vitro studies have shown excellent adhesion to human colonic mucus.1-3 The primary health attributes of B420™ are weight management and metabolic health, which may be related to its ability to support intestinal barrier integrity.4-6 In addition, Akkermansia muciniphila, a bacterial species linked to lean healthy body weight, was increased in abundance in the intestine upon B420™ supplementation.7 B420™ has demonstrated promise in both human clinical trials and animal studies in supporting weight management and inducing a better metabolic state.8-10

45 In vitro through product functionality studies

+15

Clinical trials

HEALTH-BENEFIT AREA SUPPORTED DOSING (CFU) STUDY REFERENCE
Weight management support 10 billion B420™ Stenman LK, et al. EBioMedicine. 2016. Nov;13:190–200.

For additional information, visit our B420™ bibliography

REFERENCES:
1. Klein A, Friedrich U, Vogelsang H, Jahreis G. Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC B-420 modulate unspecific cellular immune response in healthy adults. Eur J Clin Nutr. 2008;62:584-659. 2. Kok RG, de Waal A, Schut F, et al. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Appl Environ Microbiol. 1996;62:3668-3672. 3. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol. 2007;45: 454-460. 4. Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008;152:552-558. 5. Putaala H, Salusjarvi T, Nordstrom M, et al. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol. 2008;159;692-698. 6. Mokkala K, Laitinen K, Roytio H. Bifidobacterium lactis B-420 and fish oil enhance intestinal epithelial integrity in Caco-2 cells. Nutr Res. 2016;36:246-252. 7. Hibberd AA, Yde CC, Ziegler ML, et al. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Beneficial Microbes. 2018;1-16. 8. Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults—Randomized controlled trial. EBioMedicine. 2016. Nov;13:190–200. http://dx.doi.org/10.1016/j.ebiom.2016.10.036. 9. Stenman LK, Waget A, Garret C, et al. Probiotic BB-420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. Diabetology & Metabolic Syndrome. 2015;7:75. 10. Stenman LK, Waget A, Garret C, et al. Potential probiotic Bifidobacterium animalis ssp. lactis B-420 prevents weight gain and glucose intolerance in diet-induced obese mice. Beneficial Microbes. 2014;5:437-445.
The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
ARE YOU A HEALTHCARE PROFESSIONAL?
YES
NO